| 1.435 0.015 (1.05%) | 04-25 11:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.91 | 1-year : | 2.11 |
| Resists | First : | 1.64 | Second : | 1.8 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.37 | Second : | 1.13 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.59 |
| MA(100) : | 1.52 |
MA(250) : | 1.45 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 11.1 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 1.99 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPRO ] has closed above bottom band by 26.1%. Bollinger Bands are 90.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.41 - 1.42 | 1.42 - 1.43 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value (NASDAQ:SPRO) - Seeking Alpha
Sat, 20 Apr 2024
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 200 Day Moving Average of $1.41 - MarketBeat
Fri, 15 Mar 2024
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Fri, 15 Mar 2024
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 13 Mar 2024
Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 13 Mar 2024
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 20.3 (%) |
| Held by Institutions | 26 (%) |
| Shares Short | 654 (K) |
| Shares Short P.Month | 564 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | 21.9 % |
| Operating Margin | 68.7 % |
| Return on Assets (ttm) | 10.8 % |
| Return on Equity (ttm) | 24.9 % |
| Qtrly Rev. Growth | 55 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.92 |
| EBITDA (p.s.) | 0.5 |
| Qtrly Earnings Growth | 75.3 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 3.32 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.7 |
| Price to Sales | 0.74 |
| Price to Cash Flow | -2.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|